A recent Phase 2 study in gastric cancer with the FGFR2-targeting monoclonal antibody bemaritizumab demonstrated FGFR2 overexpression via immunohistochemistry in 30% of screened patients, while other datasets suggest that the amplification of FGFR2 in tissue reaches 2.2–4% and 7.7% via ctDNA analysis [110,111]. The gene discussed is FGFR2; the disease is gastric cancer.